Skip to main content

Table 2 The associations of endocrine AEs with different immunotherapy regimens*

From: Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system

Strategy Drug N IC IC025 IC975 ROR ROR025 ROR975
Total Total ICIs 6260 2.53 2.49 2.57 6.14 5.99 6.30
Monotherapy Anti-PD-1 3398 2.26 2.20 2.31 4.99 4.82 5.16
Nivolumab 2219 2.24 2.17 2.31 4.90 4.70 5.12
Pembrolizumab 1175 2.29 2.19 2.39 5.07 4.78 5.38
Cemiplimab 4 1.60 −0.31 3.50 3.07 1.13 8.32
Anti-PD-L1 269 1.68 1.48 1.88 3.26 2.89 3.68
Atezolizumab 175 1.54 1.29 1.79 2.95 2.54 3.43
Avelumab 27 1.66 1.01 2.31 3.22 2.20 4.73
Durvalumab 67 2.07 1.66 2.47 4.31 3.37 5.49
Anti-CTLA-4 708 2.97 2.84 3.09 8.29 7.68 8.95
Ipilimumab 706 2.97 2.84 3.09 8.30 7.69 8.96
Tremelimumab 2 1.55 −1.49 4.59 2.98 0.72 12.33
Anti-CTLA-4 vs anti-PD-1   708     1.68 1.55 1.83
Anti-CTLA-4 vs anti-PD-L1   708     2.54 2.20 2.93
Polytherapy Polytherapy1 64 4.41 4.00 4.83 25.60 19.44 33.71
Polytherapy2 1664 3.15 3.07 3.24 9.58 9.11 10.07
Polytherapy3 109 4.05 3.73 4.36 18.93 15.45 23.20
Polytherapy4 27 3.96 3.31 4.61 17.68 11.67 26.78
Polytherapy vs. Monotherapy   1864     2.00 1.89 2.11
  1. *In Table 2, bold text denotes significant signals. Polytherapy1: Nivolumab+ pembrolizumab+ ipilimumab; Polytherapy2: Nivolumab+ ipilimumab; Polytherapy3: Pembrolizumab+ ipilimumab; Polytherapy4: Durvalumab+ tremelimumab. N: number of records; IC025: the lower end of the 95% confidence interval of IC. IC975: the upper end of the 95% confidence interval of IC. ROR025: the lower end of the 95% confidence interval of ROR. ROR975: the upper end of the 95% confidence interval of IC